Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma

PURPOSE: Anlotinib, a newly developed oral small-molecule receptor tyrosine kinase inhibitor (TKI), has been shown to have encouraging activity against sarcoma. The purpose of this study was to retrospectively evaluate the safety and clinical efficacy of chemotherapy combined with anlotinib plus anl...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hai-ying, Chu, Jun-feng, Zhang, Peng, Wang, Jia-qiang, Yan, Zheng, Yao, Shu-na, Yao, Zhi-hua, Liu, Yan-yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7038775/
https://www.ncbi.nlm.nih.gov/pubmed/32110053
http://dx.doi.org/10.2147/OTT.S235349

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7038775/
https://www.ncbi.nlm.nih.gov/pubmed/32110053
http://dx.doi.org/10.2147/OTT.S235349

Ejemplares similares